Taken together, these data suggest that targeted inhibition of CCR1 and CCR5 on myeloid cells alters the tumor microenvironment by reducing the number of PMN-MDSCs and M2 macrophages and by increasing the concentration of cells with a phenotype consistent with classical neutrophils. Here, CCR1 is linked to neoplasm.